Animal models of Parkinson's disease

Source Book of Models for Biomedical Research

Volumn , Issue , 2008, Pages 313-322

  Lane, Emma L ^a   Carlsson, Thomas ^a   Kirik, Deniz ^b   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

6 hydroxydopamine lesioned rat; Abnormal involuntary movements; MPTP treated nonhuman primate; Parkinson's disease

Indexed keywords

EID: 76749148961     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-285-4_34     Document Type: Chapter

References (76)

1. Meredith GE, Kang UJ. Behavioral models of Parkinson's disease in rodents: A new look at an old problem. Mov Disord 2006;21(10): 1595-1606.
2. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5(1):107-110.
3. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 1995;292(3-4): 329-332.
4. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998;152(2):259-277.
5. Visanji NP, O'Neill MJ, Duty S. Nicotine, but neither alpha4beta2 nor alpha7 nAChR subtype selective agonists, protects against a partial 6-hydroxydopamine lesion of the rat nigrostriatal tract. Neuropharmacology 2006;51(3):506-516.
6. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional defi cits, recovery and treatments. Prog Neurobiol 1996;50(2-3):275-331.
7. Schallert T, Tillerson JL. Intervention strategies for degeneration of dopamine neurons in parkinsonism: Optimising behavioural assessment of outcome. In: Innovative Models of CNS Disease: From Molecule to Therapy. Clifton, NJ: Humana Press, 1999:131-151.
8. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002;175(2):303-317.
9. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24(3):485-493.
10. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 2002;99(7):4708-4713.
11. Dunnett SB, Bjorklund A, Stenevi U, Iversen SD. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. II. Bilateral lesions. Brain Res 1981;229(2):457-470.
12. Schallert T, Lindner MD. Rescuing neurons from trans-synaptic degeneration after brain damage: Helpful, harmful, or neutral in recovery of function? Can J Psychol 1990;44(2):276-292.
13. Schallert T, De Ryck M, Whishaw IQ, Ramirez VD, Teitelbaum P. Excessive bracing reactions and their control by atropine and LDOPA in an animal analog of parkinsonism. Exp Neurol 1979;64(1): 33-43.
14. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15(5Pt. 2):3863-3875.
15. Chang JW, Wachtel SR, Young D, Kang UJ. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience 1999;88(2):617-628.
16. Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnet SB. The "staircase test": A measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991;36(2-3):219-228.
17. Barneoud P, Parmentier S, Mazadier M, Miquet JM, Boireau A, Dubedat P, Blanchard JC. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 1995;67(4):837-848.
18. Lee CS, Sauer H, Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996;72(3): 641-653.
19. Nikkhah G, Duan WM, Knappe U, Jodicke A, Bjorklund A. Restoration of complex sensorimotor behavior and skilled forelimb use by a modifi ed nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 1993;56(1):33-43.
20. Winkler C, Bentlage C, Nikkhah G, Samii M, Bjorklund A. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp Neurol 1999;155(2): 165-186.
21. Dobrossy MD, Dunnett SB. Training specificity, graft development and graft-mediated functional recovery in a rodent model of Huntington's disease. Neuroscience 2005;132(3):543-552.
22. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162(1):1-10.
23. Monville C, Torres EM, Dunnett SB. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor defi cits in the 6-OHDA model. J Neurosci Methods 2006;158(2): 219-223.
24. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 2003;84(6):1398-1410.
25. Rozas G, Guerra MJ, Labandeira-Garcia JL. An automated rotarod method for quantitative drug-free evaluation of overall motor defi cits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997;2(1):75-84.
26. Baird AL, Meldrum A, Dunnett SB. The staircase test of skilled reaching in mice. Brain Res Bull 2001;54(2):243-250.
27. Annett LE, Rogers DC, Hernandez TD, Dunnett SB. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 1992;115(Pt. 3):825-856.
28. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998;4(6):727-729.
29. Marshall JW, Ridley RM. Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species. Neurodegeneration 1996;5(3):275-286.
30. Annett LE, Martel FL, Rogers DC, Ridley RM, Baker HF, Dunnett SB. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 1994;125(2):228-246.
31. Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE. Recombinant adenoassociated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 2003;184(1):536-548.
32. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-980.
33. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 1983;80(14):4546-4550.
34. Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984;50(1-3): 85-90.
35. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292(2): 390-394.
36. Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 2005; 21(4):841-854.
37. Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease? Neurosci Lett 1991;123(1):115-118.
38. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21(17):6853-6861.
39. Colosimo C, Granata R, Del Zompo M, Piccardi MP, Perretta G, Albanese A. Chronic administration of MPTP to monkeys: Behavioural morphological and biochemical correlates. Neurochem Int 1992;20(Suppl.):279S-285S.
40. Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983;309(5):310.
41. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTPinduced parkinsonism in the Macaque monkey. J Neurosci Methods 2000;96(1):71-76.
42. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998;401(2):253-265.
43. Collier TJ, Steece-Collier K, Kordower JH. Primate models of Parkinson's disease. Exp Neurol 2003;183(2):258-262.
44. Sundstrom E, Samuelsson EB. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Pharmacol Toxicol 1997;81(5):226-231.
45. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994;270(3):1008-1014.
46. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001;125(1-2):109-125.
47. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985;50(3):435-441.
48. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: Experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999;835(1):18-26.
49. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-458.
50. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Res 1994;662(1-2):69-74.
51. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15(1):120-132.
52. Cenci MA, Tranberg A, Andersson M, Hilbertson A. Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999;94(2): 515-527.
53. Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA. Pharmacological validation of a mouse model of l-DOPAinduced dyskinesia. Exp Neurol 2005;194(1):66-75.
54. Zigmond MJ, Stricker EM. Proceedings: The effects on ingestive behaviors of damage to central dopamine-containing neurons. Psychopharmacol Bull 1974;10(3):40-41.
55. Sakai K, Gash DM. Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. Brain Res 1994;633(1-2):144-150.
56. Amalric M, Moukhles H, Nieoullon A, Daszuta A. Complex defi cits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 1995;7(5):972-980.
57. Karstaedt PJ, Kerasidis H, Pincus JH, Meloni R, Graham J, Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 1994;126(1):25-30.
58. Balcioglu A, Zhang K, Tarazi FI. Dopamine depletion abolishes apomorphine-and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: A microdialysis study. Neuroscience 2003;119(4):1045-1053.
59. Takeuchi Y, Sawada T, Blunt S, Jenner P, Marsden CD. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res 1991;562(2):301-305.
60. Guerra MJ, Liste I, Labandeira-Garcia JL. Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. Neuroreport 1997;8(16):3485-3488.
61. Perez-Otano I, Herrero MT, Oset C, De Ceballos ML, Luquin MR, Obeso JA, Del Rio J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 1991;567(1):127-132.
62. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991; 44(3):591-605.
63. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645): 839-840.
64. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000;11(1):211-213.
65. Gibb WR, Terruli M, Lees AJ, Jenner P, Marsden CD. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Mov Disord 1989;4(1): 53-74.
66. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv Neurol 1993;60:600-608.
67. Eslamboli A. Marmoset monkey models of Parkinson's disease: Which model, when and why? Brain Res Bull 2005;68(3):140-149.
68. Utley JD, Carlsson A. Relative effects of L-DOPA and its methyl ester given orally or intraperitoneally to reserpine-treated mice. Acta Pharmacol Toxicol (Copenh) 1965;23(2):189-193.
69. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999;823(1-2):1-10.
70. Corasaniti MT, Strongoli MC, Rotiroti D, Bagetta G, Nistico G. Paraquat: A useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol Toxicol 1998;83(1):1-7.
71. Höglinger GU, Oertel WH, Hirsch EC. The rotenone model of parkinsonism-the five years inspection. J Neural Transm 2006; (Suppl.)70:269-272.
72. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3(12):1301-1306.
73. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56(1):149-162.
74. Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 2006;60(2):253-255.
75. Manning-Bog AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, Langston JW, Di Monte DA. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 2006;60(2):256-260.
76. Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J 3rd, Terpstra BT, Sortwell CE, Steece-Collier K, Collier TJ. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60(2): 264-268.